Clinical Trial

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

Study acronym: PRECISE-BTN
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-11.
Trial Details
NCT Number NCT07287176
Lead Sponsor Pulse Biosciences, Inc.
Conditions Thyroid Nodule, Thyroid Goiter, Ablation
Enrollment 100 participants
Start Date 2025-08-21
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15